Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan

Hepatology Research

Volumn 45, Issue 7, 2015, Pages 745-754

  Kumada, Hiromitsu ^a   Sato, Ken ^b   Takehara, Tetsuo ^c   Nakamuta, Makoto ^d   Ishigami, Masatoshi ^e   Chayama, Kazuaki ^f   Toyota, Joji ^g   Suzuki, Fumitaka ^a   Nakayasu, Yoshiyuki ^h   Ochi, Miyoko ^h   Yamada, Ichimaro ^h   Okanoue, Takeshi ⁱ  

^a TORANOMON HOSPITAL   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^e NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

^g Sapporo Kosei General Hospital   (Japan)

^h MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

ⁱ Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

Author keywords

Genotype 2; Peginterferon; Ribavirin; Sustained virological response; Telaprevir; Treatment failure

Indexed keywords

BILIRUBIN; CREATININE; HYALURONIC ACID; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; TRIACYLGLYCEROL; URIC ACID;

ABDOMINAL DISCOMFORT; ADULT; ALOPECIA; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FEVER; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HYPERURICEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INSOMNIA; JAPANESE (PEOPLE); LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; RHINOPHARYNGITIS; STOMATITIS; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING;

EID: 84935144181     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12416     Document Type: Article

References (29)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
2. Niederau C, Lange S, Heintges T etal. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695.
3. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228-1233.
4. Wartelle-Bladou C, Folgoc GL, Bourliere M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J Viral Hepat 2012; 19: 525-536.
5. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
6. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: 134-142.
7. Jacobson IM, McHutchison JG, Dusheiko GM etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
8. Poordad F, McCone J, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
9. Izumi N, Hayashi N, Kumada H etal. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941-953.
10. Forns X, Lawitz E, Zeuzem S etal. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-1679.
11. Mangia A, Santoro R, Minerva N etal. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-2617.
12. Shiffman ML, Suter F, Bacon BR etal. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-134.
13. Sato K, Hashizume H, Yamazaki Y etal. Response-guided peginterferon-alfa-2b plus ribavirin therapy for chronic hepatitis C patients with genotype 2 and high viral loads. Heptol Res 2012; 42: 854-863.
14. Kanda T, Imazeki F, Azemoto R etal. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011; 56: 3335-3342.
15. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS. Sofosbuvir for hepatitis genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877.
16. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
17. Foster GR, Hézode C, Bronowicki JP etal. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-889.
18. Simmonds P, Mellor J, Sakuldamrongpanich T etal. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol 1996; 77: 3013-3024.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
20. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-477.
21. Suzuki A, Yamada R, Chang X etal. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402.
22. Suzuki F, Suzuki Y, Akuta N etal. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 415-421.
23. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-235.
24. European Association for the Study of the Liver. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
25. Rangnekar AS, Fontana RJ. IL 28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat 2013; 20: 377-384.
26. Kawaoka T, Hayes CN, Ohishi W etal. Predictive value of the IL 28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-414.
27. Sezaki H, Suzuki F, Hosaka T etal. Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients. Hepatol Res 2014; 44: E163-171.
28. Oze T, Hiramatsu N, Yakushijin T etal. The prospective randomized study on telaprevir at 1500mg or 2250mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. J Gastroenterol 2014; [Epub ahead of print].
29. Meyer SD, Ghys A, Foster GR etal. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat 2013; 20: 395-403.